Previous 10 | Next 10 |
Shares of The Medicines Company (NASDAQ: MDCO) are up 18.6% at 12:19 p.m. EST after Bloomberg reported that the drugmaker had gotten interest from potential acquirers, including Novartis (NYSE: NVS) . A potential suitor would be after The Medicines Company's cholesterol-lowering drug inc...
Gainers: SAExploration (NASDAQ: SAEX ) +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...
SAExploration Holdings (NASDAQ: SAEX ) +183% on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...
Jeff: Joining me on the Stock Exchange is my colleague Todd E. Hurlbut, CMT, Chief Investment Officer at Incline Investment Advisors, LLC . Todd is the creator of the Emerald Bay model featured in this column. He is known as “Trending Todd.” And yes, that is a hint about his t...
Shares of The Medicines Company (NASDAQ: MDCO) closed the trading day up 12.8% following the presentation of two phase 3 clinical trials testing cholesterol-lowering drug inclisiran at the American Heart Association's Scientific Sessions in Philadelphia. Shares of Alnylam Pharmaceutica...
Results from a Phase 3 clinical trial, ORION-9 , evaluating the effect of The Medicines Company's ( MDCO +2.3% ) inclisiran on reducing "bad" cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH), an inherited condition characterized by abnormally high levels of chole...
- Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9 further demonstrated inclisiran’s excellent safety profile, including no treatment-relate...
The Medicines Company (NASDAQ: MDCO ) is up 2% premarket on light volume in reaction to positive results from a Phase 3 clinical trial, ORION-10 , evaluating inclisiran, dosed twice per year, in patients with atheroslerotic cardiovascular disease and elevated low-density lipop...
This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 11/14/2019. Please visit our Tracking David Einhorn's Greenlight Capital Hol...
- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver ...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...